Physician profile
Suzanne R Lucot
NPI 1629110606
$72,452.09
in general payments reported to CMS, 2019-2025
19 companies · $23K in 2025
The $23K reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,530 · 2020: $112 · 2021: $9,897 · 2022: $6,184 · 2023: $13K · 2024: $16K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Honoraria: $21K · Travel and Lodging: $4,618 · Food and Beverage: $3,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,250.00 |
| Honoraria | $21,150.00 |
| Travel and Lodging | $4,618.33 |
| Food and Beverage | $3,710.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $66,112.43 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $4,081.04 | 2019-2020 | |
| Alkermes, INC. | $432.29 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $401.41 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $359.58 | 2019-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $262.59 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $162.67 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $155.75 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.69 | 2020-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $95.70 | 2025 | Cobenfy |
| Tris Pharma INC | $86.13 | 2019-2023 | Dyanavel Xr |
| Neos Therapeutics, Lp | $45.03 | 2019 | |
| Noven Therapeutics, LLC | $41.05 | 2024 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $21.39 | 2023 | Quviviq |
| Shire North American Group INC | $16.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $16.13 | 2023 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $15.19 | 2022 | |
| Lundbeck LLC | $15.16 | 2023 | Rexulti |
| Acadia Pharmaceuticals INC | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Lucot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.